Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Wood on Family Histories and Genetic Counseling
June 5th 2012, 1:58pm
Dr. Marie Wood, from the University of Vermont, on Family Histories and Genetic Counseling for Breast and Colorectal Cancers.
Two Newer Breast Cancer Therapies Not Superior to Standard Paclitaxel, Study Suggests
June 5th 2012, 6:52am
The newer and more expensive breast cancer treatments nab-paclitaxel and ixabepilone, failed to demonstrate superior efficacy versus standard care with weekly paclitaxel.
Study Finds Cymbalta Reduces Peripheral Neuropathy Pain
June 5th 2012, 6:44am
The antidepressant duloxetine relieved pain associated with chemotherapy-induced peripheral neuropathy for 59% of patients.
Pilot Study Evaluates a Proposed Quality Measure for Family History Collection and Genetic Testing Referral
June 5th 2012, 6:18am
Only half of those with breast cancer and one-quarter of those with colon cancer were referred for genetic counseling or testing by their physicians.
FDA and Industry Collaborating to Prevent Cancer Drug Shortages
June 5th 2012, 6:03am
Drug manufacturers are working with the FDA to report anticipated shortages earlier and ensure alternative sources of needed drugs are available.
Dr. Rugo on Paclitaxel Superiority in Advanced Breast Cancer
June 5th 2012, 6:01am
Dr. Hope Rugo, from the UCSK Comprehensive Cancer Center, on the First-line Superiority of Paclitaxel for Advanced Breast Cancer.
Two New BRAF-Targeted Therapies Reduce Disease Progression in Advanced Melanoma Patients
June 4th 2012, 4:31pm
Trametinib and dabrafenib delayed disease progression and showed a trend toward improved survival in patients with advanced melanoma.
Dr. Robert on the Trametinib METRIC Trial Results
June 4th 2012, 2:17pm
Dr. Caroline Robert, from the Institute Gustave Roussy in Paris, France, Discusses the MEK Inhibitor, Trametinib, METRIC Trial Results.
Dr. Demetri Discusses Regorafenib for GIST Patients
June 4th 2012, 8:56am
Dr. George Demetri, from Dana-Farber Cancer Institute, Discusses Regorafenib for Patients with GIST Trial Results.
Regorafenib Offers New Hope for Patients With Treatment-Resistant GIST
June 4th 2012, 6:15am
The oral multikinase inhibitor regorafenib reduced the risk of disease progression by 73% in patients with gastrointestinal stromal tumors who had exhausted all other treatment options.
Afatinib Prolongs PFS in Lung Cancer Trial
June 4th 2012, 6:00am
Afatinib markedly prolonged PFS compared with standard chemotherapy in patients with advanced lung adenocarcinomas that tested positive for EGFR mutations, particularly one of two common mutation types.
Bevacizumab Plus Second-Line Chemotherapy Extends Survival in Advanced Colorectal Cancer Patients
June 3rd 2012, 4:39pm
Bevacizumab plus chemotherapy as a second-line treatment for metastatic colorectal cancer improved survival among patients whose disease had progressed after first-line combination therapy with bevacizumab.
Dr. Blackwell Discusses the T-DM1 EMILIA Trial
June 3rd 2012, 9:20am
Dr. Kimberly Blackwell, from the Duke Cancer Institute, Discusses the T-DM1 EMILIA Trial
Dr. Rummel on Treanda Plus Rituxan in Indolent Lymphoma
June 3rd 2012, 8:11am
Dr. Mathias Rummel, from University Hospital Giessen in Germany, on Bendamustine Plus Rituximab in Indolent and Mantle Cell Lymphomas
Antibody Drug Conjugate T-DM1 Improves PFS in HER2-Positive Breast Cancer
June 3rd 2012, 6:02am
T-DM1 extended progression-free survival by 3.2 months in women with HER2-positive locally advanced or metastatic breast cancer.
Bendamustine Superiority in Lymphoma Regimen Confirmed
June 3rd 2012, 5:26am
Bendamustine should become the preferred chemotherapy standard of care in initial combination regimens for indolent lymphomas and mantle cell lymphoma.
With Continuous Hormonal Therapy, Certain Men With Prostate Cancer Get Marked Boost in Survival
June 3rd 2012, 5:00am
Patients with metastatic, hormone-sensitive prostate cancer and minimal disease spread experience a two-year boost in median survival when treated with continuous, rather than intermittent, hormonal therapy.
Dr. Pujade-Lauraine on the AURELIA Bevacizumab Trial
June 2nd 2012, 2:19pm
Dr. Eric Pujade-Lauraine, from Université de Paris Descartes, France, on the AURELIA Bevacizumab Trial for Platinum-Resistant Ovarian Cancer.
Dr. Topalian on the PD-1 Targeted Therapy BMS-936558
June 2nd 2012, 9:09am
Dr. Suzanne Topalian, from Johns Hopkins University School of Medicine, on the PD-1 Targeted Therapy BMS-936558
Avastin Delays Disease Progression in Platinum-Resistant Ovarian Cancer
June 2nd 2012, 6:27am
Combining bevacizumab with standard chemotherapy reduced the risk of disease progression by 52% in patients with platinum-resistant ovarian cancer.